85 results about "Programmed cell death" patented technology

The invention discloses application of an MCU (microprogrammed control unit) inhibitor in preparation of a medicine for preventing or treating intestinal ischemia-reperfusion injury, and relates to the technical field of biological medicine, and the MCU inhibitor comprises one or two of a reagent for inhibiting MCU gene expression and a reagent for inhibiting MCU protein activity. The MCU inhibitor disclosed by the invention is beneficial to relieving intestinal mucosa injury and inflammatory change of intestinal tissues, improving completeness of a villus structure, reducing pathological injury degree score of the intestinal tissues and relieving cell apoptosis degree in the intestinal tissues, so that the MCU inhibitor is beneficial to relieving programmed death of intestinal mucosa cells; as a main component, the pharmaceutical composition is beneficial for preventing or treating intestinal ischemia-reperfusion injury.

The invention provides a lung adenocarcinoma prognostic marker and a model, constructs a lung adenocarcinoma prognostic model based on mRNA and lncRNA related to programmed cell death (PCD), and synthesizes bioinformatics analysis and experiments to explore the biological effect of the lncRNA model in lung adenocarcinoma. The prognosis model covers all PCD pathways and various molecules, has stable prognosis prediction accuracy, and can provide a potential molecular target for personalized treatment. According to the method disclosed by the invention, the PCD-related mRNA and lncRNA are integrated to construct a lung adenocarcinoma diagnosis model suitable for Chinese population, so that the identification capability of tumor patient classification is enhanced from multiple aspects, the accuracy and reliability of prognosis prediction are improved, powerful support can be provided for promoting personalized treatment strategies of lung adenocarcinoma patients, and the method is suitable for popularization and application.

Disclosed are a method, a device, and an information processing program for determining, by using refractive index distribution data pertaining to an object to be observed, the region of a cell that has undergone programmed cell death in the object to be observed.

The invention relates to tilletia foetida, in particular to a tilletia foetida effect protein TlRlpA and application thereof. The invention provides a Tilletia foetida effect protein, and the amino acid sequence of the Tilletia foetida effect protein is shown as SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. The effector protein can effectively inhibit programmed death of plant cells induced by BAX, and plays an important role in inhibiting a plant defense reaction process. The invention lays a foundation for deeply researching the pathogenesis of the tilletia foetida, excavating the tilletia foetida-resistant gene of the wheat and developing the tilletia foetida-resistant wheat variety.

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

The present application provides antibodies including antigen binding fragment thereof that specifically recognizing programmed cell death 1 ligand 1 (PD-L1). Also provided are methods of making and using these antibodies.

Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. In certain embodiments, the one or more additional antigen comprises Programmed cell death ligand 1 (PDL1).

The present disclosure generally relates to binding agents capable of targeting tumor cells and / or immune cells and their use to treat cancer. The binding agents of the present disclosure comprise one or more antigen-binding domains of a single-domain antibody capable of binding to cluster of differentiation 36 (CD36), programmed cell death protein 1 (PD-1), and / or cluster of differentiation 47 (CD47). The binding agents of the present disclosure may be monospecific or multispecific and may be in monomeric or multimeric form.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

Provided is the use of a genetically engineered phage expressing a first peptide targeting a Programmed Cell Death protein 1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) and a second peptide targeting a cancer-related antigen for enhanced efficacy in cancer treatment. Thus, provided are methods for improved anti-cancer therapy, especially in the treatment of solid tumors, by using a recombinant phage that is capable of specifically targeting the PD-1 / PD-L1 pathway and specifically targeting a cancer antigen, as well as compositions and kits useful for such treatment methods.

To provide engineered PD-1 antibodies and uses thereof.SOLUTION: In some aspects, provided herein are antibodies that bind to PD-1. Antibodies provided herein, in some cases, agonize PD-1 signaling. Antibodies provided herein, in some cases, have modified Fc region. In other aspects, provided herein are compositions, methods of use, methods of making, and kits relating to antibodies that bind to PD-1. In some aspects, provided herein are methods of suppressing immune cells expressing programmed cell death 1 (PD-1), the methods comprising contacting the immune cells with an antibody that specifically binds to PD-1 and enhances an interaction between PD-1 and PD-L1 on a surface of the immune cells.SELECTED DRAWING: None

The invention provides an application of OGA as an inhibition target in preparation of drugs for treating GBC, and relates to the technical field of biomedicine.According to a specific verification test, it is found that GBC cells transfer OGA to neurons through EVs, so that glycosylation of RIPK1 is inhibited, phosphorylation and activation of RIPK1 are promoted, and finally neuronal necroptosis is induced. RIPK1 is a core factor for regulating and controlling cell survival, inflammatory response and programmed death, and is activated through a compound IIb pathway under the action of exogenous OGA. EV-induced invasion and necroptosis can be remarkably inhibited through neuron OGA knock-down, so that the aim of treating GBC is achieved.

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

The invention discloses a rice disease resistance defense regulation gene SRWD2 as well as an encoding protein and application thereof. According to the invention, a rice disease spot-like mutant tb18 is taken as an experimental material, a rice disease resistance defense regulation gene SRWD2 is separated through strategies such as MutMap positioning and transgene complementation, the nucleotide sequence of the gene is shown as SEQ ID NO.1, and the sequence of a protein coded by the gene is shown as SEQ ID NO.2. The biological function of the SRWD2 gene is analyzed, a theoretical basis is provided for clarification of a molecular mechanism of programmed cell death and defense reaction of plants, the gene mutation site is introduced into the plants through gene engineering or conventional means, the disease resistance can be remarkably enhanced, and the gene has important application value in the aspect of disease-resistant variety cultivation of the plants.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

The invention belongs to the technical field of bioelectricity medicine and cell therapy, and particularly relates to a system for carrying out intracellular electric treatment based on ultrahigh-frequency ultrashort pulses and application of the system. The system comprises a high-voltage ultrashort pulse generation module, a control module and an adherent cell processing module, wherein the high-voltage ultrashort pulse generation module is respectively connected with the control module and the adherent cell processing module; the control module presets a plurality of pulse parameter combinations, the high-voltage ultrashort pulse generation module outputs a pulse electric field with preset parameters according to an instruction sent by the control module, and the pulse electric field acts on an organelle through the adherent cell processing module. High-frequency ultrashort pulses are adopted, the unique electric field distribution characteristic of the high-frequency ultrashort pulses can penetrate through cell membranes without causing permanent damage, and the high-frequency ultrashort pulses directly act on specific organelles such as mitochondria, endoplasmic reticulum and lysosome. And the system can flexibly induce four main programmed cell death modes, is suitable for different treatment requirements, and is beneficial to precise medical treatment.

The invention discloses an application of an lncRNA-MALAT1 / miR-145 / BNIP3 regulation axis in preparation of a medicine for treating hemorrhagic shock ischemia reperfusion intestinal injury. In existing treatment, conventional liquid resuscitation easily causes serious inflammation and pathological apoptosis, the intestinal barrier repair effect is limited, and the molecular mechanism is not completely clarified. The invention discloses that a regulatory axis participates in an intestinal injury process through a ceRNA mechanism (MALAT1 is used as miR-145 sponge to inhibit regulation of BNIP3 and mediate controlled programmed cell death instead of pathological apoptosis), and provides a new molecular target for treatment. The medicine aiming at the regulation shaft can relieve inflammatory response, reduce pathological apoptosis and promote intestinal barrier repair, and has a good application prospect.

Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

The disclosure provides amino acid sequence variants of programmed cell death protein 1 (PD-1) that can bind to either or both of its ligands, PDL-1 or PDL-2. The disclosure relates to ligand-binding fragments of the PD-1 variant sequences, conjugates, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., PD-1 variants and ligand-binding fragments thereof, in the treatment of checkpoint pathway-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, as well as diseases, disorders, and conditions associated with immune deficiency, immune insufficiency, and / or subjects who are immune compromised.

The invention discloses a DNA polymerase theta (Pol theta) and programmed cell death-ligand 1 (PD-L1) double-target inhibitor as well as a preparation method and medical application of the DNA polymerase theta (Pol theta) and programmed cell death-ligand 1 (PD-L1) double-target inhibitor. The compound disclosed by the invention is shown as a general formula (I), can target Pol theta and PD-L1 at the same time, plays a dual role in inhibiting the Pol theta and the PD-L1, and can be used for preparing a medicine for treating homologous recombination repair (HR) defect type cancers. (I).

The present invention provides a means or the like capable of temporarily inhibiting expression of PD-1 or CTLA-4 protein. The present invention relates to an antisense oligonucleotide or the like capable of hybridizing with a nucleic acid sequence of an mRNA precursor and / or mature mRNA of Programmed Cell Death 1 (PD-1) protein or Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) protein and suppressing or inhibiting the expression of PD-1 protein or CTLA-4 protein.

Disclosed herein is a composition for enhancing an abscopal effect of radiation, including a lymphocyte activation gene-3 (LAG-3) inhibitor and a programmed cell death protein-1 (PD-1) inhibitor. One aspect relates to a method of enhancing an abscopal effect of radiation by co-administering a composition including an LAG-3 inhibitor and a PD-1 inhibitor in conjunction with radiotherapy in the treatment of cancer (e.g., triple-negative breast cancer).

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I). The present invention also relates to the use of the compounds of formula (I) to inhibit the programmed cell death 1 (PD1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

This invention discloses a prognostic model and construction method for cervical squamous cell carcinoma, belonging to the fields of bioinformatics and oncology. The construction method is based on a set of genes related to programmed cell death, integrating multi-omics data of cervical squamous cell carcinoma patients from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Cancer Genome Characterization Project (CGCI). After standardized preprocessing, differential expression analysis, bootstrap resampling combined with univariate Cox regression for initial screening, consensus screening using multiple machine learning algorithms, and finally, multivariate Cox proportional hazards regression analysis to identify three core independent prognostic genes and construct a risk scoring model. This model has undergone multi-dimensional validation and optimization, demonstrating robust predictive performance. The method of this invention is standardized and highly reproducible, and the constructed model has high accuracy and strong generalization ability, providing a reliable tool for individualized prognostic assessment and clinical decision-making for cervical squamous cell carcinoma patients.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

The present disclosure generally relates to binding agents that are capable of targeting tumor cells and / or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding domains of single domain antibodies which are capable of binding to Cluster of Differentiation 36 (CD36), to Programmed Cell Death protein 1 (PD-1) and / or to Cluster of Differentiation 47 (CD47). The binding agents of the present disclosure are monospecific or multispecific and may be in the form of monomers or multimers.

The invention provides a protein related to regulation and control of growth and development states of litsea cubeba, a biological material and application thereof, relates to the technical field of variation or genetic engineering, and discloses a key gene LcTGA10 for regulating and controlling the growth and development states of litsea cubeba, the gene LcTGA10 is transferred into arabidopsis thaliana, the gene expression quantity of PDCD of the arabidopsis thaliana can be increased, and the gene expression quantity of PDCD of the arabidopsis thaliana can be increased. When the expression of the LcTGA10 gene is inhibited, the gene expression quantity of PDCD is reduced. PDCD is a programmed cell death regulation gene, and growth and development of litsea cubeba can be effectively promoted by inhibiting expression of specific LcTGA10 in litsea cubeba.